iMDx posts Q2 loss as FDA review of GraftAssureDx continues
Go back to iMDx posts Q2 loss as FDA review of GraftAssureDx continues| BIO-RAD LABORATORIES (NYSE: BIO) | Delayed: 371.06 -5.91 (1.57%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $376.97 | 52 Week High | $174.02 | |||
| Open | $379.92 | 52 Week Low | $122.03 | |||
| Day High | $382.01 | P/E | 120.08 | |||
| Day Low | $369.33 | EPS | $3.09 | |||
| Volume | 94,338 | |||||
| (NASDAQ: IMDX) | Delayed: 3.98 -0.12 (2.93%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.10 | 52 Week High | $ | |||
| Open | $4.04 | 52 Week Low | $ | |||
| Day High | $4.15 | P/E | N/A | |||
| Day Low | $3.91 | EPS | $ | |||
| Volume | 86,736 | |||||
